South Korea’s Chong Kun Dang Pharmaceuticals Corp. said that it struck a deal potentially worth $1.3 billion with Swiss pharma giant Novartis AG for its CKD-510 candidate for neurological and cardiovascular diseases, propelling its shares upward 26.11% by market closing of Nov. 6. With the “largest ever” deal in its history, shares of the Seoul-based pharmaceutical (KOSPI:185750) on the Korea Exchange rose by 26.11%, or ₩26,500, closing at ₩128,000 ($98.70). Read More
Top-line results from Moonlake Immunotherapeutics AG’s phase II study of sonelokimab treating active psoriatic arthritis encouraged the company but discouraged investors. Read More
With drug shortages in the U.S. both a growing and chronic problem, a congressional committee is once again probing how the FDA is handling the issue. Read More
The BioWorld Biopharmaceutical Index (BBI) fell through October, ending the month up just 0.98%. It remains above its low point of the year, when it was down 3.65% at the end of February. Read More
Electrical stimulation of the spinal cord has restored the ability to walk normally to a patient whose chronic Parkinson’s disease (PD) had led to severe motor deficits, researchers reported in the Nov. 6, 2023, online issue of Nature Medicine. Read More
Demand for its COVID-19 vaccine might be declining, but Biontech SE is putting its revenue to good use, picking up rights to a bispecific antibody candidate from Biotheus Inc. in exchange for $55 million up front and potentially more than $1 billion in development, regulatory and sales milestones. Read More
Multinational pharma companies like Moderna Inc. and Sanofi SA are setting up mRNA R&D centers in Australia and are banking on the country’s decades of mRNA expertise to bring new therapeutics to the clinic and to serve as regional hubs in Asia Pacific, speakers said during the Ausbiotech 2023 conference held Nov 1-3 in Brisbane, Australia. Read More
New hires and promotions in the biopharma industry, including: Acelyrin, Adverum, Anavex, Avalyn, Biogen, Daiichi Sankyo, Diaccurate, Hudson, Neurobo, Onconano, T-knife, Volastra. Read More
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Abionyx, Ardelyx, Aslan, Aurinia, Kronos, Mendus, Molecular Templates, Otsuko, Sorriso, T3D, Terns, Travere, Werewolf. Read More
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: BMS, Acumen, Biocryst, Clearside, Diaccurate, Frequency, Inotrem, Korro, Orum, Starton, Vaccitech. Read More
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Angiex, Briacell, Plus. Read More
